1
. The authors argue that the naturally occurring CD4 + CD25
+ regulatory T (T Reg )-cell population is defective in rheumatoid arthritis and possibly in other autoimmune inflammatory diseases (such as multiple sclerosis and type 1 . As an alternative to the ex vivo expansion of T Reg cells we also propose in our Review the use of adoptive immunotherapy with inducible regulatory T cells, such as T R 1 cells, which are generated in vitro in the presence of the antigen and interleukin-10. This approach overrides the need for isolating and expanding T Reg cells from patients with ongoing acute and chronic disease 1 . We agree with Dr Bayry and colleagues that it is still completely uncertain whether adoptive transfer of ex vivo expanded or generated regulatory T cells per se is sufficient to downregulate inflammation and revert active diseases. We indeed suggest that "Regulatory T-cell-based immunotherapy should not be envisaged as an all-or-nothing approach to re-establish immunological tolerance on its own. " 1 An alternative approach that combines regulatory T-cell-based adoptive immunotherapy with other therapeutic interventions that are able to counteract the non-tolerogenic inflammatory milieu and the function of activated effector T cells might result in a better clinical outcome.
The different method proposed by Bayry and colleagues to first induce functionally fit regulatory T cells in vivo in the patients followed by their ex vivo expansion could also be considered. The observations that treatment of rheumatoid arthritis patients with tumour-necrosis factor blockade leads to a significant increase in the number of circulating T Reg cells 9, 10 and to the generation of a newly differentiated population of regulatory T cells 11 are clearly interesting. However, these cells do not mediate longterm tolerance in vivo 12 . Furthermore, the demonstration that these in vivo re-fit regulatory T cells can be isolated and expanded in vitro while maintaining their regulatory activity is still missing.
